Nomura has spun off its life science venture, Phase4 Ventures. Some of the venture’s assets under management have been sold to funds managed by HarbourVest Partners. Phase4 Ventures will run the new fund, Phase4 Ventures III, for HarbourVest and an existing fund for Nomura.
The firm and its team, led by Denise Pollard-Knight, will continue to be based in London. The new fund, Phase4 Ventures III, includes Albireo Pharma and Nabriva Therapeutics, spun-out from Novartis/Sandoz and Astra Zeneca respectively, and Chroma Therapeutics in the U.K.
Click here for the release from Phase4 Ventures.